59
Participants
Start Date
February 9, 2018
Primary Completion Date
April 30, 2020
Study Completion Date
August 14, 2020
HTD1801
HTD1801 tablets, 250 mg
Placebo
tablets manufactured to mimic HTD1801 tablets
Mount Sinai - Icahn School of Medicine, New York
Walter Reed National Military Medical Center, Bethesda
Mercy Medical Center, Baltimore
Wake Forest Baptist Health, Winston-Salem
Cumberland Research Associates, Fayetteville
University of Miami, Miami
Florida Research Institute, Lakewood Rch
Vanderbilt University Medical Center, Nashville
Gastro One, Germantown
Gastrointestinal Associates, Flowood
Michigan Medicine University of Michigan, Ann Arbor
Washington University School of Medicine, St Louis
Pinnacle Clinical Research, San Antonio
Pinnacle Clinical Research, Austin
University of Colorado, Denver, Aurora
South Denver Gastroenterology, PC, Englewood
Arizona Liver Health, Chandler
Arizona Liver Health, Tuscon
Keck School of Medicine of USC, Los Angeles
Cedars-Sinai Medical Center, Los Angeles
Fresno Clinical Research Center, Fresno
Swedish Medical Center, Seattle
University of Washington, Seattle
Yale School of Medicine, New Haven
Aspen Woods Clinic, Calgary
Toronto Centre for Liver Disease, Toronto General Hospital, Toronto
HighTide Biopharma Pty Ltd
INDUSTRY